aquipta
abbvie deutschland gmbh & co. kg - atogepant - migreenihäired - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
ryeqo
gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomüoom - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
vyepti
h. lundbeck a/s - eptinezumab - migreenihäired - valuvaigistid - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
circadin
rad neurim pharmaceuticals eec sarl - melatoniin - unehäirete ja hoolduse häired - psühhoeptikumid - circadin on näidustatud, kui monoteraapia primaarse unetuse lühiajaliseks raviks, mida iseloomustab halva kvaliteediga uni vähemalt 55 saavatel või üle.
evra
gedeon richter plc. - norelgestromin, ethinyl estradiol - kontraceptsioon - suguhormoonid ja genitaalsüsteemi, - naiste rasestumisvastane vahend. evra on mõeldud viljakas eas naistel. ohutus ja efektiivsus on tõestatud naistel vanuses 18 kuni 45 aastat.
ioa
n.v. organon - nomegestrol atsetaat, östradiooli - kontraceptsioon - suguhormoonid ja genitaalsüsteemi, - suukaudne kontratseptsioon.
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaktsiinid - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastilised ained - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
butifen 400 mg õhukese polümeerikattega tablett
ratiopharm gmbh - ibuprofeen - õhukese polümeerikattega tablett - 400mg 16tk; 400mg 10tk; 400mg 30tk; 400mg 40tk; 400mg 20tk; 400mg 6tk; 400mg 12tk; 400mg 24tk; 400mg 14tk
migsun õhukese polümeerikattega tablett
orion corporation - sumatriptaan+naprokseen - õhukese polümeerikattega tablett - 85mg+500mg 9tk